[8-K] MARIMED INC. Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

MariMed Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders re-elected four directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—to serve until the next annual meeting or until successors are elected and qualified.

Stockholders also approved, on an advisory basis, the appointment of M&K CPAs PLLC as MariMed’s independent auditors for the 2026 fiscal year, with a substantial majority of votes cast in favor.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/08/2026 - 04:18 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2026

MARIMED INC.

(Exact name of registrant as specified in its charter)

Delaware

0-54433

27-4672745

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

10 Oceana Way

Norwood, MA 02062

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (781) 277-0007


(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class

Ticker symbol(s)

Name of each exchange on which registered

Not Applicable.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.07. Submission of Matters to Vote of Security Holders.

On June 4, 2026, MariMed Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote on the matters listed below. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 23, 2026. At the Annual Meeting, the Company's stockholders:

•re-elected four directors of the Company to serve until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified ("Election of Directors"); and

•approved, on an advisory basis, the appointment of M&K CPAs PLLC as the Company's independent auditors for the 2026 fiscal year the ("Advisory Approval of Auditors").

The specific votes were as follows:

1. Election of Directors:


VOTES
NAME	FOR	WITHHELD	BROKER NON-VOTE
Jon R. Levine	111,339,122	14,355,396	119,765,107
Edward Gildea	110,868,950	14,825,568	119,765,107
David Allen	110,854,282	14,840,236	119,765,107
Eva Selhub, M.D.	111,358,888	14,335,630	119,765,107

2. Advisory Approval of Auditors:


VOTES
FOR	AGAINST	ABSTAIN/WITHHELD
229,335,138	15,550,371	574,116

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	MARIMED INC.

Dated: June 8, 2026
	By:	/s/ Mario Pinho
		Mario Pinho
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did MariMed (MRMD) stockholders vote on at the 2026 Annual Meeting?

Stockholders voted on re-electing four directors and approving, on an advisory basis, M&K CPAs PLLC as independent auditors for the 2026 fiscal year. Both the director slate and auditor appointment received strong support.

Were MariMed (MRMD) directors re-elected at the 2026 Annual Meeting?

Yes. All four nominated directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—were re-elected to the MariMed board. They will serve until the next annual meeting or until their successors are duly elected and qualified.

How did MariMed (MRMD) stockholders vote on the independent auditor for 2026?

Stockholders approved, on an advisory basis, the appointment of M&K CPAs PLLC as MariMed’s independent auditors for the 2026 fiscal year, with 229,335,138 votes for, 15,550,371 against, and 574,116 abstaining.

What were the vote totals for MariMed (MRMD) director Jon R. Levine in 2026?

Jon R. Levine received 111,339,122 votes for his re-election, with 14,355,396 votes withheld and 119,765,107 broker non-votes recorded. These results supported his continuation as a director until the next annual meeting.

What does broker non-vote mean in MariMed (MRMD) 2026 voting results?

Broker non-votes represent shares held in street name where brokers did not receive voting instructions on non-routine matters. For MariMed’s 2026 director elections, 119,765,107 broker non-votes were reported for each nominee, but these did not count as votes for or against.

Filing Exhibits & Attachments

3 documents